(56) **References Cited**

U.S. PATENT DOCUMENTS

5,916,589	A	6/1999	Hauer et al.
5,929,030	A	7/1999	Hamied et al.
5,951,971	A	9/1999	Kawashima et al.
5,962,014	A	10/1999	Hauer et al.
5,962,017	A	10/1999	Hauer et al.
5,962,019	A	10/1999	Cho et al.
5,977,066	A	11/1999	Cavanak
5,981,479	A	11/1999	Ko et al.
5,981,607	A	11/1999	Ding et al.
5,998,365	A	12/1999	Sherman
6,004,566	A	12/1999	Friedman et al.
6,007,840	A	12/1999	Hauer et al.
6,008,191	A	12/1999	Singh
6,008,192	A	12/1999	Al-Razzak et al.
6,022,852	A	2/2000	Klokkers et al.
6,024,978	A	2/2000	Hauer et al.
6,046,163	A	4/2000	Stuchlik et al.
6,057,289	A	5/2000	Mulye
6,159,933	A	12/2000	Sherman
6,197,335	B1	3/2001	Sherman
6,254,860	B1	7/2001	Garst
6,254,885	B1	7/2001	Cho et al.
6,267,985	B1	7/2001	Chen et al.
6,284,268	B1	9/2001	Mishra et al.
6,294,192	B1	9/2001	Patel et al.
6,306,825	B1	10/2001	Cavanak
6,323,204	B1	11/2001	Burke
6,346,511	B1	2/2002	Singh et al.
6,350,442	B2	2/2002	Garst
6,413,547	B1	7/2002	Bennett et al.
6,420,355	B2	7/2002	Richter et al.
6,468,968	B2	10/2002	Cavanak et al.
6,475,519	B1	11/2002	Meinzer et al.
6,486,124	B2	11/2002	Olbrich et al.
6,544,953	B2	4/2003	Tsuzuki et al.
6,555,526	B2	4/2003	Matsuo
6,562,873	B2	5/2003	Olejnik et al.
6,569,463	B2	5/2003	Patel et al.
6,582,718	B2	6/2003	Kawashima
6,656,460	B2	12/2003	Benita et al.
6,872,705	B2	3/2005	Lyons
6,984,628	B2 *	1/2006	Bakhit et al. 514/20.8
7,202,209	B2	4/2007	Chang
7,276,476	B2	10/2007	Chang et al.
7,288,520	B2	10/2007	Chang et al.
7,297,679	B2	11/2007	Chang
7,501,393	B2	3/2009	Tien et al.
8,211,855	B2	7/2012	Chang et al.
8,288,348	B2	10/2012	Chang et al.
2001/0003589	A1	6/2001	Neuer et al.
2001/0014665	A1	8/2001	Fischer et al.
2001/0036449	A1	11/2001	Garst
2002/0012680	A1	1/2002	Patel et al.
2002/0013272	A1	1/2002	Cavanak et al.
2002/0016290	A1	2/2002	Floc'h et al.
2002/0016292	A1	2/2002	Richter et al.
2002/0025927	A1	2/2002	Olbrich et al.
2002/0045601	A1	4/2002	Kawashima
2002/0107183	A1	8/2002	Petszulat et al.
2002/0119190	A1	8/2002	Meinzer et al.
2002/0165134	A1	11/2002	Richter et al.
2003/0021816	A1	1/2003	Kang et al.
2003/0044452	A1	3/2003	Ueno
2003/0055028	A1	3/2003	Stergiopoulos et al.
2003/0059470	A1	3/2003	Muller
2003/0060402	A1	3/2003	Cavanak et al.
2003/0087813	A1	5/2003	Or et al.
2003/0104992	A1	6/2003	Or et al.
2003/0108626	A1	6/2003	Benita et al.
2003/0109425	A1	6/2003	Or et al.
2003/0109426	A1	6/2003	Or et al.
2003/0133984	A1	7/2003	Ambuhl et al.
2003/0143250	A1	7/2003	Hauer et al.
2003/0147954	A1	8/2003	Yang et al.
2003/0166517	A1	9/2003	Fricker et al.
2005/0014691	A1	1/2005	Bakhit et al.
2005/0059583	A1	3/2005	Acheampong
2007/0015691	A1	1/2007	Chang
2007/0027072	A1	2/2007	Tien et al.
2007/0087962	A1	4/2007	Tien et al.
2007/0149447	A1	6/2007	Chang et al.
2007/0299004	A1	12/2007	Acheampong et al.
2008/0039378	A1	2/2008	Graham et al.
2008/0070834	A1	3/2008	Chang et al.
2008/0146497	A1	6/2008	Graham et al.
2008/0207495	A1	8/2008	Graham et al.
2009/0131307	A1	5/2009	Tien et al.
2010/0279951	A1	11/2010	Morgan et al.
2011/0009339	A1	1/2011	Schiffman
2011/0294744	A1	12/2011	Morgan et al.
2012/0270805	A1	10/2012	Chang et al.
2013/0059796	A1	3/2013	Chang et al.

FOREIGN PATENT DOCUMENTS

EP	0547229	1/1993
EP	0760237	3/1997
WO	95-31211	11/1995
WO	00-00179	1/2000
WO	01-32142	5/2001
WO	01-41671	6/2001
WO	02-09667	2/2002
WO	02-49603	6/2002
WO	03-030834	4/2003
WO	03-053405	7/2003

OTHER PUBLICATIONS

Akpek, Esen Karamursel et al, A Randomized Trial of Topical Cyclosporin 0.05% in Topical Steroid-Resistant Atopic Keratoconjunctivitis, Ophthalmology, 2004, 476-482, 111.

Angelov, O. et al, Preclinical Safety Studies of Cyclosporine Ophthalmic Emulsion, Adv Exp Med Biol, 1998, 991-995, 438.

Angelov, O. et al, Safety Assessment of Cyclosporine Ophthalmic Emulsion in Rabbits and Dogs, XIth Congress of the European Society of Ophthalmology, 1997, 25-28, 1-5, Soc. Ophthalmol Eur., Hu.

Ardizzone Sandro et al, A Practical Guide to the Management of Distal Ulceratve Colitis, Drugs, 1998, 519-542, 55(4).

Banic, Marko et al, Effect of Cyclosporine in a Murine Model of Experimental Colitis, Digestve Diseases and Sciences, Jun. 2002, 1362-1368, 47(6).

Bonini, S. et al, Vernal Keratoconjunctivitis, Eye, 2004, 345-351, 18.

Brewster, Marcus et al, Enhanced Delivery of Ganciclovir to the Brain Though the Use of Redox Targeting, Antimicrobial Agents and Chemotherapy, Apr. 1994, 817-823, 38(4).

Brewster, Marcus et al, Intravenous and Oral Pharmacokinetic Evaluation of a 2-Hydroxypropyl-β-cyclodextrin-Based Formulation of Carbamazepine in the Dog: Comparison with Commercially Available Tablets and Suspensions, Journal of Pharmaceutical Sciences, Mar. 1997, 335-339, 86(3).

Brewster, Marcus et al, Preparation, Characterization, and Anesthetic Properties of 2-Hydroxypropyl-β-cyclodextrin Complexes of Pregnanolone and Pregnenolone in Rat and Mouse, Journal of Pharmaceutical Sciences, Oct. 1995, 1154-1159, 84(10).

Brinkmeier, Thomas et al, Pyodermatitis-Pyostomatitis Vegetans: A Clinical Course of Two Decades with Response to Cyclosporine and Low-Dose Prednisolone, Acta Derm Venereol, 2001, 134-136, 81.

Castillo, Jose M. Benitez Del et al, Influence of Topical Cyclosporine A and Dissolvent on Corneal Epithelium Permeability of Fluorescein, Documenta Ophthalmologica, 1995, 49-55, 91.

Cheeks, Lisa et al, Influence of Vehicle and Anterior Chamber Protein Concentration on Cyclosporine Penetration Through the Isolated Rabbit Cornea, Current Eye Research, 1992, 641-649, 11(7).

Database WPI Week 200044, Derwent Pub. Ltd., London, GB; An 2000-492678 & JP2000/143542, 2000, 2 Pages.

Ding, Shulin et al, Cyclosporine Ophthalmic O/W emulsion: Formulation and Emulsion Characterization, Pharm Res, 1997, 1 page, 14 (11).

Donnenfeld, Eric D., The Economics of Using Restasis, Ophthalmology Management, Oct. 2003, 3 pages, US.

Drosos, A. A. et al, Efficacy and Safety of Cyclosporine-A Therapy for Primary Sjogren's Syndrome, Ter. Arkh., 1998, 77-80, 60(4).